Positive CLIP‑170 (CL170) Antibodies — Clinical Significance and Next Steps
Bold take: A positive CLIP‑170 antibody is a rare, non-standard autoantibody with no validated disease association or management implications; treat it as an incidental, research-level finding and do not anchor diagnosis or therapy on it. 1
What this antibody means (and doesn’t)
- CLIP‑170 is a microtubule plus‑end–tracking protein; autoantibodies against it have been described only in small case reports without a reproducible disease link (reported in isolated SLE, limited scleroderma, glioblastoma, idiopathic pleural effusion) and are not part of any diagnostic criteria or guideline-driven panel. Morbidity/mortality/QOL are not improved by acting on this result alone. 2
- No major rheumatology, hepatology, neurology, or thrombosis guideline includes CLIP‑170 antibodies in diagnostic algorithms. Prioritize established, outcome-relevant autoantibodies instead (ANA/ENA, anti‑dsDNA, APS aPL tests) when clinically indicated. 1, 3, 4, 5, 3
Action algorithm (driven by morbidity, mortality, QOL)
- Verify the result
- Confirm assay validity with the lab:
- Method used, titer, pattern, and controls; repeat once in a new sample if low‑titer or unexpected to exclude technical artifact. Low-titer, non-standard antibodies are common and often non-specific. 1
- Do NOT treat or label a disease based on CLIP‑170 alone
- No immunosuppression or surveillance is warranted solely for CLIP‑170 positivity. 1
- If there are clinical red flags, investigate with guideline-backed tests only:
- Suspicion for SLE or systemic CTD (rash/photosensitivity, oral ulcers, serositis, cytopenias, nephritis, inflammatory arthritis):
- Suspicion for antiphospholipid syndrome (thrombosis, pregnancy morbidity):
- Suspicion for autoimmune hepatitis (elevated AST/ALT, hyper‑IgG):
- Use standard panel (ANA, SMA, anti‑LKM‑1, ±SLA/LP) and liver biopsy if indicated; CLIP‑170 has no role. 6
- Suspicion for autoimmune encephalitis:
- When to ignore CLIP‑170
- Asymptomatic individuals or presentations with alternative explanations: document as an incidental non-validated autoantibody and proceed with standard-of-care workup only if clinically indicated. This avoids overtesting, overtreatment, and iatrogenic harm. 1
Pitfalls and how to avoid them
- Pitfall: Anchoring on rare/non-validated antibodies.
- Pitfall: Treating serology without syndrome-level clinical correlation.
- Pitfall: Not repeating unexpected, low-titer or discordant results.